Patents by Inventor Matthias Heinrich Nettekoven
Matthias Heinrich Nettekoven has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7902184Abstract: The present invention relates to compounds of formula I and their pharmaceutically acceptable salts wherein formula I is: wherein X, Y, Z, R1 and R2 are as defined in the description and claims. The compounds of the present invention act as antagonists and/or inverse agonists at the histamine 3 receptor and are useful for the treatment and/or prevention of diseases such as obesity, metabolic syndrome (syndrome X), and other eating disorders.Type: GrantFiled: May 21, 2007Date of Patent: March 8, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Olivier Roche
-
Patent number: 7786128Abstract: Provided are compounds of the formula I: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable salts thereof, and methods of using said compounds. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.Type: GrantFiled: May 2, 2008Date of Patent: August 31, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Konrad Bleicher, Matthias Heinrich Nettekoven, Philippe Pflieger, Stephen Roever
-
Patent number: 7786143Abstract: The present invention relates to compounds of formula I wherein R1, R2 and R3 are as defined in the description and claims. It further relates to pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: August 10, 2006Date of Patent: August 31, 2010Assignee: Hoffman-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Olivier Roche
-
Patent number: 7754736Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: October 7, 2008Date of Patent: July 13, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Jean-Marc Plancher, Olivier Roche, Rosa Maria Rodriguez-Sarmiento
-
Patent number: 7629346Abstract: The present invention relates to compounds of the formula I: wherein R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.Type: GrantFiled: May 30, 2007Date of Patent: December 8, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Paul Hebeisen, Hans Iding, Matthias Heinrich Nettekoven, Ulrike Obst Sander, Stephan Roever, Urs Weiss, Beat Wirz
-
Patent number: 7612076Abstract: The present invention relates to compounds of formula I wherein R1, R2, X, Y, Z and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: October 7, 2008Date of Patent: November 3, 2009Assignee: Hoffman-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Olivier Roche, Rosa Maria Rodriguez-Sarmiento
-
Patent number: 7608617Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: June 22, 2007Date of Patent: October 27, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Silvia Gatti McArthur, Cornelia Hertel, Matthias Heinrich Nettekoven, Jean-Marc Plancher, Susanne Raab, Olivier Roche, Rosa Maria Rodriguez-Sarmiento, Franz Schuler
-
Patent number: 7605163Abstract: The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.Type: GrantFiled: October 31, 2007Date of Patent: October 20, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stalder
-
Patent number: 7595314Abstract: A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.Type: GrantFiled: July 22, 2008Date of Patent: September 29, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Daniela Alberati-Giani, Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stalder
-
Publication number: 20090192136Abstract: A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.Type: ApplicationFiled: July 22, 2008Publication date: July 30, 2009Inventors: Daniela Alberati-Giani, Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stalder
-
Patent number: 7538132Abstract: The present invention is concerned with aryl-isoxazole-4-carbonyl-pyrrole-2-carboxylic acid amide derivatives of formula wherein R1, R2, R3, R4, and R5, and m are as defined herein and with their pharmaceutically acceptable acid addition salts. This class of compounds have high affinity and selectivity for GABA A ?5 receptor binding sites and therefore may be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.Type: GrantFiled: September 13, 2006Date of Patent: May 26, 2009Assignee: Hoffman-La Roche Inc.Inventors: Bernd Buettelmann, Bo Han, Henner Knust, Matthias Heinrich Nettekoven, Andrew William Thomas
-
Patent number: 7534891Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: October 14, 2005Date of Patent: May 19, 2009Assignee: Hoffman-La Roche Inc.Inventors: Silvia Gatti McArthur, Cornelia Hertel, Matthias Heinrich Nettekoven, Susanne Raab, Hans Richter, Olivier Roche, Rosa Maria Rodriguez-Sarmiento, Franz Schuler
-
Patent number: 7528135Abstract: The present invention relates to compounds of formula I wherein R1, R2 and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: November 30, 2005Date of Patent: May 5, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Olivier Roche, Rosa Maria Rodriguez-Sarmiento
-
Publication number: 20090069311Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: ApplicationFiled: October 7, 2008Publication date: March 12, 2009Inventors: Matthias Heinrich Nettekoven, Jean-Marc Plancher, Olivier Roche, Rosa Maria Rodriguez-Sarmiento
-
Publication number: 20090042903Abstract: The present invention relates to compounds of formula I wherein R1, R2, X, Y, Z and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: ApplicationFiled: October 7, 2008Publication date: February 12, 2009Inventors: Matthias Heinrich Nettekoven, Olivier Roche, Rosa Maria Rodriguez-Sarmiento
-
Patent number: 7462617Abstract: The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other d 1iseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.Type: GrantFiled: September 1, 2004Date of Patent: December 9, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Daniela Alberati-Giani, Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stalder
-
Patent number: 7459480Abstract: This invention relates to compounds of the formula wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACC? inhibitors.Type: GrantFiled: October 29, 2004Date of Patent: December 2, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Luca Claudio Gobbi, Marcel Gubler, Werner Neidhart, Matthias Heinrich Nettekoven
-
Patent number: 7456175Abstract: The present invention relates to compounds of formula I wherein R1, R2, X, Y, Z and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: December 12, 2005Date of Patent: November 25, 2008Assignee: Hoffman-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Olivier Roche, Rosa Maria Rodriguez-Sarmiento
-
Patent number: 7456174Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: January 17, 2006Date of Patent: November 25, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Jean-Marc Plancher, Olivier Roche, Rosa Maria Rodriguez-Sarmiento
-
Patent number: 7432255Abstract: The present invention relates to compounds of formula I and their pharmaceutically acceptable salts wherein in formula I is: wherein R1 to R4 are as defined in the description and claims. The compounds of the present invention are useful for the treatment and/or prevention of diseases which are associated with the modulation of histamine 3 (H3) receptors.Type: GrantFiled: April 26, 2007Date of Patent: October 7, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Olivier Roche